Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D3PD8C
|
|||
| Drug Name |
AXS-05
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Depression [ICD-11: 6A70-6A7Z] | Phase 3 | [1] | |
| Alzheimer disease [ICD-11: 8A20; ICD-10: G30, G30.9; ICD-9: 331] | Phase 2/3 | [2], [3], [4] | ||
| Company |
Axsome Therapeutics
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | N-methyl-D-aspartate receptor (NMDAR) | Target Info | Antagonist | [5] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04019704) A Trial of AXS-05 in Patients With Major Depressive Disorder (GEMINI). U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 3 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 4 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 5 | Clinical pipeline report, company report or official report of Axsome Therapeutics. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.